THE COMPANY

Nanopharm was founded by Prof Rob Price in 2002 shortly after which he was joined by Dr Jag Shur. Together they oversaw its growth from a scientific start-up to a fully-fledged high-end CRO business that is recognised as an international leader in its field.

‍

CHALLENGE

Whilst Nanopharm continued to grow strongly as an independent entity, Rob and Jag concluded that the company, employees and clients would all benefit from the business becoming part of a larger organisation with the support, reach and synergies that would support Nanopharm’s continued development on a global stage. After receiving several approaches, Rob and Jag decided it was time to seek a new home for Nanopharm.

We set about identifying the right buyer with whom they and the business could continue to grow. We worked to draw up a list of appropriate potential buyers and assessed their relative merits and suitability against the criteria set by Rob and Jag.

We advised the shareholders on the current and future value of the business and importantly, how to maximise that during the transaction. This spanned from correct preparation and accounting detail, to articulating the strategic vision.

With Nanopharm positioned as a key disruptor in the respiratory CRO space, we helped potential buyers to understand the true value of the business by illustrating the upside potential.

‍

OUTCOME

We introduced Nanopharm to Aptar Pharma, its eventual new owner. We worked closely with Rob and Jag, the business, Aptar and respective advisors to manage the due diligence and closing process to a tight deadline. The deal was completed only THREE working days after the initial deadline set out some three months earlier.

‍

TESTIMONIAL

"We were initially concerned about the value that Shaw & Co might add to our deal. We didn’t understand the true value of their expertise and just how critical their input would become. Now on the other side, we wouldn’t hesitate to instruct them again."

"
Their strategic positioning of the business, attention to detail and expertise in executing the deal delivered us a multiple of the investment we made in Shaw & Co’s appointment."

Prof. Rob Price
Founder & Chief Scientific Officer, Nanopharm